key: cord-0859149-j60jzpil
authors: Carr, Siobhán B; Cosgriff, Rebecca; Harutyunyan, Satenik; Middleton, Peter G; Ruseckaite, Rasa; Ahern, Susannah; Daneau, Géraldine; Filho, Luiz Vicente R F da Silva; Stephenson, Anne L; Cheng, Stephanie Y; Melo, Joel; Corvol, Harriet; Burgel, Pierre-Régis; Nährlich, Lutz; McKone, Edward; Colombo, Carla; Salvatore, Marco; Padoan, Rita; Abdrakhmanov, Olzhas; Gulmans, Vincent; Byrnes, Catherine A; Amelina, Elena; Kondratyeva, Elena; Zhekayte, Elena; Kashirskaya, Nataliya; Zampoli, Marco; Pastor-Vivero, M Dolores; Mondejar-Lopez, Pedro; de Monestrol, Isabelle; Jung, Andeas; McClenaghan, Elliot; Brownlee, Keith; Rizvi, Samar; Goss, Christopher H; Elbert, Alexander; Faro, Albert; Gutierrez, Hector; Marshall, Bruce C
title: COVID-19 vaccine prioritisation for people with cystic fibrosis
date: 2021-04-15
journal: J Cyst Fibros
DOI: 10.1016/j.jcf.2021.03.028
sha: 5abe585dd88a67c73f8d76d4b50696a7ffafebc6
doc_id: 859149
cord_uid: j60jzpil

nan

Of the 21 countries responding to the survey, 15 had started their national vaccination programme. For most countries the policy for highest prioritisation within the population targeted three priority groups: long term nursing home residents with their care providers, health care workers and people over 80 years of age; the priority order for these was not consistent across the countries. People with CF then appeared in different prioritisation groups from "no priority" in 7 countries to the highest priority tier after these top three. Most countries with an order of roll out tended to just state "high risk" people rather than list people with CF specifically, although 6 appeared to do so. In some countries roll out may differ across regions.

We are aware that premarket purchase has allowed some countries to get ahead in delivery of COVID-19 vaccines and that global equitable access should be a priority (4). Nevertheless, the disparity in prioritisation for people with CF across the globe is a concern.

Evidence in CF confirms the increased risk for post-transplant patients and shows those with advanced lung disease are at higher risk of hospitalisation and intervention following infection with SARS-CoV-2 than others with CF (2). People with CF aged under 18 have also been shown to be at risk of hospitalisation from SARS-CoV-2 infection (3). In most countries, people in this clinically vulnerable group have had to self-isolate for the last 10 months.

People with CF need vaccine distribution strategies that are aggressive, predictable and adhere to science and medicine. These strategies must be clearly communicated so that people with CF know how, when and where they can receive vaccination. Disparities in the availability of vaccinations for people with CF mean we must continue to advocate for them to get prioritisation.

The Global Registry Harmonization Group

A multinational report to characterise SARS-CoV-2 infection in people with cystic fibrosis

The global impact of SARS-CoV-2 in 181 people with cystic fibrosis

Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: an international observational study

The authors have no conflicts of interest to declare relating to this work.